First-in-class CMV treatment showed better efficacy in refractory patients with genetic resistance than those without; US FDA advisory committee will separately consider benefit-risk in each type of patient. On the safety side, taste disturbance is the only adverse event that stands out.

US-based giant Amgen has seen its Mvasi biosimilar become the sole bevacizumab product listed on Australia’s Pharmaceutical Benefits Scheme.

Amid a case of re-infection of a vaccinated healthcare worker in western China’s Xi’an city, and ongoing debate over domestic vaccines' efficacy, increasing attention is being paid in China to raising inoculation rates for COVID-19 and moving towards herd immunity.

China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.